|
(Health-NewsWire.Net, October 16, 2021 )
Market Overview
The global peptide cancer vaccine market size was valued at US$ YY million in 2020 and is estimated to reach US$ YY million by 2028, growing at a CAGR of YY % during the forecast period (2021-2028).
Cancer peptide vaccines are a promising cancer treatment that can cause tumors to produce cancer-specific cytotoxic T lymphocytes (CTLs).
View full report: https://www.datamintelligence.com/research-report/peptide-cancer-vaccine-market
Market Dynamics
The factors driving the global peptide cancer vaccine market are the rising incidence of cancer. The increasing potential of peptides for cancer treatment is expected to drive market growth.
Rising cases of cancer is expected to drive the global peptide cancer vaccine market growth
According to the International Agency for Research on Cancer (IARC), 1 in 5 persons are estimated to develop cancer during their lifetime, with 1 in 8 men and 1 in 11 women die from it. According to these latest figures, over 50 million people are alive within five years of a previous cancer diagnosis. Globally, aging populations and socioeconomic risk factors continue to be the key drivers of this growth. Breast cancer will affect 2.3 million women globally in 2020, with 685 000 fatalities. According to WHO, breast cancer was diagnosed in 7.8 million women in the previous five years as of 2020, making it the most common cancer in the world.
A range of alternative tactics is available to address the progression of cancer and disease propagation, demonstrating the promise of peptides in cancer treatment. Targeted therapy, which uses peptides to target cancer cells while avoiding normal cells directly, is becoming a viable alternative to traditional chemotherapy. A peptide can be used directly as a cytotoxic agent in various ways, or it can act as a carrier of cytotoxic chemicals and radioisotopes by targeting cancer cells preferentially. For the treatment of breast and prostate cancers, peptide-based hormone therapy has been extensively explored and used. Hence, the rise in the incidence rate of cancer is expected to drive market growth.
Increasing potential of peptides for cancer treatment can be hoped to drive the market growth in the forecast period
Peptides can be used to treat cancer in a variety of methods. This includes the use of peptides as medications (for example, as angiogenesis inhibitors), tumor-targeting agents that transport cytotoxic pharmaceuticals and radionuclides (targeted chemotherapy and radiation therapy), hormones, and vaccinations. There are many peptide-based cancer treatment strategies available. Peptides can bind to various receptors and are involved in a variety of metabolic pathways, making them possible diagnostic tools and biomarkers in the course of cancer. Although several approaches based on the use of immune cells or immune molecules have been examined, active immunization appears to be one of the most promising strategies for treating cancer. In recent times, the concept of cancer vaccinations has evolved into clinical research to determine the best way to give vaccines based on specific antigens to promote anticancer immunity. Vaccines generated from the protein sequence of putative tumor-associated or particular antigens are used to treat malignant cells in this manner.
Tumor cells produce tumor-associated antigens (TAAs) that the immune system may identify (T cells). Many TAAs have already been discovered and described at the molecular level. These TAAs can be injected into cancer patients to elicit a systemic immune response that could lead to the death of cancer cells spread throughout the body. The host's immune system is either triggered de novo or restimulated to generate an efficient, tumor-specific immune response that may eventually lead to tumor regression, referred to as active immunotherapy or vaccination. A tumor antigen is any protein or peptide produced by a tumor cell with an aberrant structure due to mutation. Mutations in the relevant gene cause aberrant proteins to be generated. Several clinical trials in patients with metastatic cancer are looking into the therapeutic potential of active immunisation or vaccination with TAA peptides.
Enzymatic degradation and lack of awareness of peptide is expected to hamper the market growth
It is still difficult to rationally create peptide-based vaccinations that can successfully prevent and treat cancer cell growth. The complexity of the interactions involved is difficult to predict. The involvement of surrounding molecules in vivo adds to the complexity, resulting in decreased biological activity and undesired side effects. Additionally, the delivery of peptide-based vaccines into the cell for further processing and presentation to effector cells is a hurdle that must be addressed. Appropriate chemical entities can be included in peptide-based vaccinations to increase cellular absorption and biological activation. Finally, peptide-based vaccines' vulnerability to enzymatic degradation necessitates non-natural amino acids, retro-inversion, and/or cyclization to improve bioavailability, hence lowering the required dosage with minimal adverse effects. Recent research on peptide vaccine optimization in animal models shows that the peptide formulations, adjuvants, and delivery routes used in most clinical trials were not optimal.
COVID-19 Impact Analysis
COVID-19 has affected the healthcare industry moderately. To stop its spread, government-imposed lockdown. People are fearful they may experience occupational effects and negative health from the COVID-19 pandemic. The clinical trials for peptide cancer vaccines were halted during the pandemic due to the fear of COVID. This has affected the global peptide cancer vaccine market moderately due to limitations to avoid transmission of COVID. Hence, the global peptide cancer vaccine market has seen a decrease in its market.
Market Segmentation
Global Peptide Cancer Vaccine Market- By Clinical Trial
Phase 1
Phase 2
Phase 3
Global Peptide Cancer Vaccine Market- By Application
Prostate Cancer
Breast Cancer
Lung Cancer
Pancreatic Cancer
Other
Global Peptide Cancer Vaccine Market- By Region
North America
Europe
South America
Asia Pacific
Middle East and Africa
The American Association for Cancer Research (AACR) is the world's first and biggest cancer research organization dedicated to making cancer a thing of the past. The American Association for Cancer Research is dedicated to the prevention and cure of cancer. The AACR promotes cancer research and related biomedical science through its programs and services, accelerates new research findings among scientists and others dedicated to the fight against cancer, promotes science education and training, and advances global understanding of cancer aetiology, prevention, diagnosis, and treatment.
Download free sample: https://www.datamintelligence.com/download-sample/peptide-cancer-vaccine-market
Competitive Landscape
The global peptide cancer vaccine market is highly competitive. The factors driving the key players are the increasing incidence of cancer and the rising demand for cancer treatment.
Some of the major key players in the global peptide cancer vaccine market are Sumitomo dainippon pharma, Sellas, ISA Pharmaceuticals, Generex Biotechnology, Immatics, Shionogi & Co., Ltd., BrightPath Biotherapeutics, and AMAL Therapeutics (AMAL)
Sumitomo Dainippon Pharma
Overview: Every day, Sumitomo Dainippon Pharma Co., Ltd. strives to fulfill its company objective of "contributing broadly to society through value creation based on innovative research and development activities for the enhancement of healthcare and richer lives of people globally. The company's mission is to put all of its efforts into the research and development of new pharmaceuticals, with the goal of providing innovative and valuable pharmaceutical solutions to people not only in Japan but also around the world.
Product Portfolio: The company focuses on pharmaceutical products and research areas of Psychiatry & Neurology, Oncology, and Regenerative Medicine & Cell Therapy.
Key Development: On July 1, 2020, Sumitomo Dainippon Pharma Co., Ltd. merged its subsidiaries in the United States, Boston Biomedical, Inc. ("Boston Biomedical") and Tolero Pharmaceuticals, Inc. ("Tolero"), renamed the company Sumitomo Dainippon Pharma Oncology, Inc.
Topic's you may be interested, CD Antigen Cancer Therapy Market, Cell Signaling Market, Metastatic Prostate Cancer Treatment Market, Embolotherapy Market, Cancer CDK Inhibitors Market
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
|
